Stocks posted a great performance this week. Is it time to sell the burgeoning rebound?
The U.S. Food and Drug Administration is requiring labels of all long-acting opioids to say they should be used strictly for patients in severe pain, a response to surging overdoses and deaths each year from the widely used pain medicines. The FDA, in a notice on its website on Wednesday, said it had approved the proposed changes, which will indicate that such drugs should only be used for severe pain. Currently, the labels indicate they are appropriate for patients with moderate and severe pain. Extended-release opioids will also fall under the proposed FDA guidelines.
Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. A U.S. court in March invalidated a patent extending Pfizer's marketing exclusivity for Celebrex to Dec. 2, 2015. Celebrex's basic chemical patent is set to expire this May. Pfizer said on Thursday it would continue to defend the patent extending its marketing exclusivity.
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
The Dow notched up substantial gains during a holiday shortened week, boosted by several positive factors.
* Drugmaker to hire 10-20 pct more doctors in-house * GSK hopes for long-term competitive advantage with revamp LONDON, April 17 (Reuters) - Drugmaker GlaxoSmithKline - hit by bribery claims in five countries - is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices. Following a decision to cut commercial ties with outside doctors, GSK expects to increase its in-house team of physicians by 10-20 percent over the next year or so from around 1,500 at present, Chief Medical Officer James Shannon told Reuters.
Scientists and drugmakers are pioneering a new kind of clinical trial that changes the way cancer drugs are studied, potentially cutting both the time and cost of bringing them to market. Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer (TLO: PF-U.TI - news) at the same time within one trial. The aim is to quickly pinpoint medicines that can fight advanced lung cancer by targeting specific rare genetic mutations - and it upends the normal approach of putting a particular drug at the centre of a study. Harpal Kumar, chief executive of charity Cancer Research UK, which is working on the 25-million-pound ($42-million) project with the two drugmakers, said the new approach would "re-write the rule book on how we do clinical trials".
Dear Jenny McCarthy, Here's How Many Lives Could Be Saved Cheaply By Making Vaccines More Widely AvailableYahoo 04/16 13:38 ET
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.